Andere Sprachen Veru Inc.

Aktien

A2DV3C

US92536C1036

VERU

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 18.04.2024			% 5 Tage	% 1. Jan.
1.42 ^USD	+22.41%		-20.67%	+97.22%

15.04.	VERU INC. : Oppenheimer bekräftigt seine Kaufempfehlung	ZM
01.04.	Veru Inc. meldet Ergebnis für das erste Quartal zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Veru Announces Date of 2024 Annual Meeting of Shareholders	01.04.
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	01.04.
Veru Reschedules Annual Meeting of Shareholders	25.03.
Veru Reschedules Annual Meeting of Shareholders	22.03.
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13.03.
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13.03.
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss	12.03.
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	12.03.
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q	28.02.
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN	21.02.
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss	20.02.
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	20.02.
Veru Reports Fiscal 2024 First Quarter Financial Highlights	08.02.
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs	06.02.
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	06.02.
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	31.01.
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024	25.01.
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss	08.01.
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	08.01.
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs	19.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Veru Inc.

Aktien

A2DV3C

US92536C1036

VERU

Andere Sprachen

Filter